NCT04448808 - Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

January 2, 2025

Study Completion Date

January 2, 2025

Conditions

Posttraumatic Stress Disorder

Interventions

DRUG

BX-1

BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.

DRUG

Placebo

Placebo of BX-1, oral solution

Trial Locations (4)

Berlin St. Hedwig, Berlin

Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Psychiatrie und Psychotherapie, Berlin

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Zentralinstitut für Seelische Gesundheit Mannheim, Mannheim